SYDNEY, June 8, 2026, 02:03 AEST
Pro Medicus Ltd saw a strong rebound this week but now faces an index shakeup after S&P Dow Jones Indices decided to cut the medical-imaging software company from the S&P/ASX 50 later this month. The ASX is closed Monday for the King’s Birthday holiday, so traders will have to wait until the next session to react to the late-Friday announcement.
That’s now front of mind since shares took off. Pro Medicus ended Friday at A$165.64, a gain of 4.03% on the day and about 25% higher than last week’s finish at A$132.26, according to Tiger Brokers market data.
Healthcare names pushed higher in an otherwise weaker session for Australian equities. The S&P/ASX 200 lost 0.70% to end at 8,625.10 on Friday. CSL surged 5.75%, leading a sector rally of more than 3%. Sigma Healthcare inched up 0.34% and Pro Medicus finished 4.03% stronger.
Contract headlines moved the stock. Pro Medicus said on June 4 that its U.S. wing, Visage Imaging, renewed a five-year deal worth A$16 million with The Ohio State University Wexner Medical Center. The new agreement adds Visage 7 Workflow and Visage 7 Cardiology Imaging. It’s a transaction-based contract, so revenue could rise above base levels depending on use.
CEO Sam Hupert said the contract renewal was a sign customers are aiming to “retire legacy solutions and continue to scale” the Visage 7 platform. Total renewals for the year hit A$141 million, the company said. ASX Announcements
Pro Medicus shares got a boost from two U.S. contracts announced earlier in the week, according to a Reuters market note on Friday. The deals were a seven-year A$16 million agreement and a five-year A$28 million deal. The note also said the stock had climbed about 22% for the week, pacing for its biggest gain since October 2013.
Deal sizes are getting less attention from analysts lately, with duration now in focus. RBC’s Jackson Lee said the Ohio State renewal points to customers “expanding usage rather than cutting deal lengths,” which has helped reduce worries about AI-native rivals pushing for shorter contracts. Tiger Brokers
Morgans analyst Iain Wilkie said after speaking with Pro Medicus and industry sources that the company was “never been better positioned” and continues to have a “structurally strong competitive position.” Morgans kept its buy rating and A$210 target. RBC held its sector-perform rating and A$195 target. Tiger Brokers
ALS Ltd is set to join the S&P/ASX 50, bumping out Pro Medicus, according to S&P Dow Jones Indices. The change will take effect before the open on June 22. This move comes as part of a planned index rebalance, which typically leads funds tracking the benchmark to tweak their positions near the changeover.
The catch is clear. After jumping nearly 25% in five days, the stock has little room if trading stumbles, and any selling from index funds could land while some investors still hesitate over AI risks, the stock’s price, and how fast hospital contracts actually bring in revenue.
ASX traders face a flow-versus-fundamentals test this week. The market will focus on Tuesday’s first print, ASX 50-related turnover, and fresh S&P Dow Jones pro forma index files out after the June 12 close. The rebalance takes effect June 22.
